Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
EAST SETAUKET, N.Y., Dec. 19, 2011 /PRNewswire/ -- An article in the early edition (December 12, 2011) of the Proceedings of the National Academy of Sciences USA , reported that Lixte's investigational drug, LB-205, was shown to have therapeutic potential in a laboratory model of Gaucher disease (http://www.pnas.org/content/early/2011/12/08/1119181109.full.pdf+html).
John Kovach, MD, founder and president of Lixte said, "This is a novel use of the class of drugs known as histone deacetylase inhibitors (HDACi's). HDACi's have been used clinically primarily as an anticancer treatments. To our knowledge, this is the first time HDACi's have been shown to have therapeutic potential in a model of Gaucher disease. We were pleased that the effectiveness of LB-205 compared favorably with a clinically approved HDACi. Primary treatment for many Gaucher disease patients is injection of the enzyme, glucocerebrosidase, which decreases the toxic accumulation of glucocerebroside in many tissues. Unfortunately, in some patients, the brain is significantly affected by glucocerebroside accumulation and the injected enzyme does enter the brain readily. Although the effectiveness of HDACi's for Gaucher treatment remains to be proven in clinical studies, the discovery is intriguing because some HDACi's, like LB-205, penetrate the brain and may be effective given by mouth rather than injection, simplifying long term management."
About Lixte Biotechnology Holdings, Inc.
Lixte is a cancer drug discovery company, using biomarker
technology and innovative chemistry to develop new potentially more
effective anti-cancer drugs. It has lead compounds in two classes
of drugs, protein phosphatase inhibitors for which a US patent was
recently issued with world-wide patent applications pending for a
lead compound LB-100 and structural variants , and novel histone
deacetylase inhibitors for which broad patent applications are also
pending. The Company is targeting treatments for several types
common and rarer but devastating cancers. The primary emphasis is
on the most common and most aggressive type of brain cancer of
adults, glioblastoma multiforme and other cancers of neural tissue
(nerve and brain), including medulloblastoma, the most common brain
tumor of children, and neuroblastoma, the most common cancer of
children, as well as non-neural cancers of adults, including breast
and pancreatic cancer, melanomas and sarcomas.
Forward-Looking Statements
This announcement contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933,
and Section 21E of the Securities Exchange Act of 1934. For
example, statements regarding the Company's financial position,
business strategy and other plans and objectives for future
operations, and assumptions and predictions about future product
demand, supply, manufacturing, costs, marketing and pricing factors
are all forward-looking statements. These statements are generally
accompanied by words such as "intend," anticipate," "believe,"
"estimate," "potential(ly)," "continue," "forecast," "predict,"
"plan," "may," "will," "could," "would," "should," "expect" or the
negative of such terms or other comparable terminology. The Company
believes that the assumptions and expectations reflected in such
forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to
have been correct or that the Company will take any action that the
Company may presently be planning. However, these forward-looking
statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto in the SEC
Report on Form 10-QSB for the quarter ending September 30,
2011.
For additional information, please see: www.Lixte.com
SOURCE Lixte Biotechnology Holdings, Inc.
CONTACT: CONTACT: Investor Relations: Jeff Ramson, +1-212-792-4284,
jramson@proactivecrg.com,
Pro-Active Capital Resources Group.
Web Site: http://www.Lixte.com
Posted: December 2011
